Commercial IRB Disputes FDA Warning Letter

Drug Industry Daily
KEYWORDS FDA / IRB / Warning
A A
The Patient Advocacy Council, a Alabama-based commercial institutional review board (IRB), is disputing an FDA warning letter accusing it of failing to protect "economically and educationally disadvantaged subjects" in clinical trials it oversaw.

To View This Article:

Login

Subscribe To Drug Industry Daily